Is bivalirudin an alternative anticoagulant for extracorporeal membrane oxygenation (ECMO) patients? A systematic review and meta-analysis
Li DH, Sun MW, Zhang JC, Zhang C, Deng L, Jiang H (2021) · Thrombosis Research · n=0
Perfil del estudio
- Diseño
- systematic review and meta-analysis of 10 studies (9 in meta-analysis): RCTs, cohort, and case-control studies
- Tamaño de la muestra (n)
- —
- Intervención
- Bivalirudin anticoagulation for ECMO
- Comparador
- Heparin anticoagulation for ECMO
- Punto final primario
- Hospital mortality, ECMO duration, major bleeding, thrombosis, circuit interventions
- Resultado primario
- In adults, bivalirudin associated with lower hospital mortality (OR 0.65, 95% CI 0.44-0.95, p=0.03) and lower thrombosis (OR 0.55, 95% CI 0.37-0.83, p=0.004); no significant differences in major bleeding, ECMO duration, or circuit interventions
- Duración del seguimiento
- Hospital discharge
- PMID
- 35007937
Hallazgos clave
- 35% relative reduction in hospital mortality with bivalirudin in adults
- 45% relative reduction in thrombotic events
- No difference in bleeding, ECMO duration, or circuit interventions
- Authors transparent about low evidence quality
- Complements parallel meta-analyses from Hasegawa, Huang, Wieruszewski
Limitaciones
- All 10 included studies retrospective observational
- Significant heterogeneity could not be eliminated
- Authors explicitly note low overall evidence level
- Lack of standardization in anticoagulation targets
- Not applicable to whole-leech hirudotherapy
Implicaciones clínicas
Li 2021 provides early systematic review evidence supporting bivalirudin survival and thrombosis benefits in adult ECMO, consistent with parallel syntheses. For ASH, this work demonstrates how aggregated retrospective observational evidence builds the case for the synthetic thrombin inhibitor pharmaceutical pathway, structurally separate from the K040187 device-leech US clinical practice. The author transparency about evidence quality models good methodological practice.
Estudios relacionados
Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial
Fuchs J, Cannon CP (1995)
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial
Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW (2009)
Experience with pharmacologic leeching with bivalirudin for adjunct treatment of venous congestion of head and neck reconstructive flaps
Harun A, Kruer RM, Lee A, Boahene K, Byrne PJ, Richmon JD (2018)
Heparin and Bivalirudin in Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Review Article
Wang G, Qi K, Li X, Zuo S, Zhang R, Zhao Y, Sun S, Zhang J, Liu X (2024)